Opendata, web and dolomites

URO-BEST

UROthelial carcinoma Biomarker based diagnostic tEST

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 URO-BEST project word cloud

Explore the words cloud of the URO-BEST project. It provides you a very rough idea of what is the project "URO-BEST" about.

multicenter    freedom    patent    worldwide    380    survival    signatures    12       clinically    cancers    surveillance    market    diagnosis    million    samples    vs    60    yearly    validate    1st    uro    diagnosed    urovysion    stat    transurethral    assay    91    providers    expressed    hence    patients    cystoscopies    differentially    specificity    operate    molecular    figures    diagnostic    cystoscopy    controls    malignancies    performance    genetic    tests    healthcare    cytology    nmp22    billion    usa    bta    international    pct    costly    ongoing    estimate    initial    rates    risk    tool    requiring    launch    treat    2013    reduce    validated    first    protecting    urine    demonstrating    invasive    presenting    japan    genes    monitor    healhty    81    gt    exists    superior    complications    standard    frequent    detected    filed    relapse    gold    averaging    70    perfom    13    biotech    cancer    secure    unmet    patient    licensing    opportunity    fina    discriminating    94    believe    525    40    invention    urologists    combined    sensitivity    200million    bladder    global    costliest    near    biomarker    period   

Project "URO-BEST" data sheet

The following table provides information about the project.

Coordinator
FINA BIOTECH S.L. 

Organization address
address: CAMINO DE LAS HUERTAS 2, EDIFICIO 1
city: POZUELO DE ALARCON
postcode: 28223
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.finabiotech.es/investigation/diagnostics/dx-bladder-cancer/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FINA BIOTECH S.L. ES (POZUELO DE ALARCON) coordinator 50˙000.00

Map

 Project objective

Bladder cancer is among the five most common malignancies worldwide: more than 380.000 new cases are diagnosed yearly. If detected early, 5-year survival is high (94%),but >70% of diagnosed patients will relapse within this period. The current gold standard diagnostic tool is combined cytology and cystoscopy which is costly and highly invasive requiring transurethral access and presenting the risk of important complications. Due to high relapse rates, surveillance requires frequent cystoscopies, averaging 13 controls per patient after initial diagnosis. Hence, bladder cancer is one of the costliest cancers to treat and monitor. Only in the USA, Europe and Japan, more than 4.5 million cystoscopies are conducted yearly, 40% for 1st diagnosis and 60% for surveillance, at a cost near to $2 billion to healthcare providers. Urologists believe that an opportunity exists to reduce the number of SURVEILLANCE cystoscopies with a reliable, cost-effective, robust, easy-to-perfom and non-invasive assay. URO-BEST addresses this unmet need. Based on signatures of 2, 5,10 and 12 differentially-expressed genes, this test has been clinically validated in a multicenter international study on 525 urine samples demonstrating 81% sensitivity and 91% specificity in discriminating cases vs. healhty patients for first diagnosis, figures comparable to that of the gold standard and superior to other existing molecular diagnostic products (Urovysion, NMP22, BTA Stat). We estimate the current market for bladder cancer biomarker based tests at greater than > $200million. Fina Biotech has filed European and PCT patent applications protecting the invention in 2013. Fina Biotech aims to clinically validate the diagnostic performance of the genetic signatures in patients under SURVEILLANCE for its launch to the market: advance ongoing discussions with potential partners for global licensing,increase urologists awareness and secure freedom to operate.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "URO-BEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "URO-BEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More